DUBLIN–(BUSINESS WIRE)–The “World: Contact Lenses – Market Report – Analysis and Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering. The report provides an in-depth analysis of the global contact lenses market. It presents t…
Author: Business Wire
Avedro Announces Agreement with the FDA for the First U.S. Pivotal Phase 3 Trial of an Epi-on Cross-Linking Treatment for Patients with Progressive Keratoconus
WALTHAM, Mass.–(BUSINESS WIRE)–#clinicaltrials–Avedro Announces Agreement with FDA for First U.S. Pivotal Phase 3 Trial of Epi-On Cross-Linking Treatment for Patients with Progressive Keratoconus.
Aerpio Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB: ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today announced that President and Founder, Joseph Gardner, Ph.D., will present at the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 8:00 a.m. Eastern Time in New York, N.Y. Dr. Gardner will provide a corporate overview and business update. The presentation will be webcast live and may be accessed b
SeniorWell Expands Leadership Team with Executive Hire
CHICAGO–(BUSINESS WIRE)–SeniorWell Expands Leadership Team with Executive Hire, New CEO will expand the company’s footprint and optimize patient experience
Resumen: EyeArt™, el software de detección de retinopatía diabética basado en la inteligencia artificial de Eyenuk Inc. ha sido probado con el dispositivo portátil de imágenes vinculado a un teléfono inteligente en un nuevo estudio que señala el potencial …
LOS ÁNGELES–(BUSINESS WIRE)–EyeArt™, el software de detección de retinopatía diabética basado en la inteligencia artificial de Eyenuk Inc. ha sido probado con el dispositivo portátil de imágenes vinculado a un teléfono inteligente en un nuevo estudio que señala el potencial para la detección retiniana masiva altamente sensible y rentable Eyenuk, Inc., líder en el desarrollo de soluciones avanzadas basadas en inteligencia artificial (IA) clínicamente probadas para la identificación de enfermed
Groundbreaking Research Reveals Accuracy of PerkinElmer’s High Volume NIPT Platform
WALTHAM, Mass.–(BUSINESS WIRE)–PerkinElmer, Inc.: WHAT: PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the publication of a research study describing the technology behind the Vanadis NIPT system. The article titled “Imaging Single DNA Molecules for High Precision NIPT” is published online on March 14 in Nature Scientific Reports. WHY: Prenatal screening based on cell-free DNA (cfDNA), also referred to as non-invasive prenatal testing (NIPT),
Kala Pharmaceuticals to Present at the Oppenheimer 28th Annual Healthcare Conference
WALTHAM, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals announces that it will present at the Oppenheimer 28th Annual Healthcare Conference in New York, NY.
Glendale Eye Medical Group Partners with Trilogy Eye Medical Group (Acuity Eye Group™)
PASADENA, Calif. & GLENDALE, Calif.–(BUSINESS WIRE)–#acuityeyegroup–Glendale Eye Medical Group partners with Trilogy Eye Medical Group (Acuity Eye Group™).
Aerie Pharmaceuticals to Present at the Oppenheimer & Co. 28th Annual Healthcare Conference
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that Richard Rubino, Chief Financial Officer, will present in a fireside chat discussion at the Oppenheimer & Co. 28th Annual Healthcare Conference on Tuesday, March 20, 2018 at 8:00am Eastern T
Global Optical Instruments and Lens Manufacturing Markets to 2022 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Optical Instruments and Lens Manufacturing: Global Markets to 2022” report has been added to ResearchAndMarkets.com’s offering. This research report categorizes the optical instrument and lens market by type. Segment type …
ソウル半導体の太陽光LED “SunLike”、中国イーライトのスマートランプに採用
韓国安山市–(BUSINESS WIRE)–（ビジネスワイヤ） — 世界的なLED （発光ダイオード）専業メーカーのSeoul Semiconductor Co., Ltd. (本社：韓国安山市、代表理事：李貞勲、以下「ソウル半導体」)は、革新的なIT専門企業シャオミ(Xiaomi)社のエコチェーンカンパニーであり、インテリジェント照明業界のリーダーであるYeelight (www.yeelight.com、代表：Jiang Zhaoning、以下「イーライト社」）が、スマートフォンアプリで、学習時間、照明の色、明るさ調節(調光)などを制御可能で、Amazon AlexaやGoogle Assistantにも対応したスマートホームシステムとしても使えるスマートスタンド(製品名：Yeelight LED Desklamp Pro)にソウル半導体のSunLikeを光源として採用したと明らかにした。 Yeelight LED Desklamp Proは、イーライト社が卓越した技術によって照明との関わり方を変え、最も快適な光を提供するという経営哲学のもとに、スマートランプ市場に投入した
EyeArt™, le logiciel de dépistage de la rétinopathie diabétique à base d’IA d’Eyenuk Inc., a été testé sur un dispositif d’imagerie portable fonctionnant à partir d’un smartphone dans le cadre d’une étude indiquant la possibilité d’un dépistage…
LOS ANGELES–(BUSINESS WIRE)–EyeArt™, le logiciel de dépistage de la rétinopathie diabétique à base d’IA d’Eyenuk Inc., a été testé sur un dispositif d’imagerie portable fonctionnant à partir d’un smartphone dans le cadre d’une étude indiquant la possibilité d’un dépistage rétinien de masse hautement sensible et offrant un bon rapport coût/efficacité Eyenuk, Inc., un leader dans le développement de solutions avancées et étayées cliniquement à base d’intelligence artificielle (IA) pour l’identi
KI-gestützte Software EyeArt™ von Eyenuk Inc. für Screening auf diabetische Retinopathie in neuer Studie mit tragbarem, smartphonegestütztem Bildgebungsgerät getestet – legt Potential für hochempfindliche, aber kosteneffektive Reihen-Netzhaut-Screenings …
LOS ANGELES–(BUSINESS WIRE)–KI-gestützte Software EyeArt™ von Eyenuk Inc. für Screening auf diabetische Retinopathie in neuer Studie mit tragbarem, smartphonegestütztem Bildgebungsgerät getestet – legt Potential für hochempfindliche, aber kosteneffektive Reihen-Netzhaut-Screenings nahe Eyenuk, Inc., ein führender Entwickler moderner, klinisch gestützter, für künstliche Intelligenz (KI) kompatibler Lösungen zur Erkennung von Erkrankungen über die Analyse von Netzhautbildern, hat heute die Verö
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
CINCINNATI–(BUSINESS WIRE)–Aerpio Pharmaceuticals, Inc. (OTCQB:ARPO), a biopharmaceutical company focused on advancing first-in-class treatments for ocular diseases, today reported financial results for the fourth quarter and full year ended December 31, 2017. “Over the past year, Aerpio has made tremendous progress in the development of AKB-9778, our first-in-class Tie2-activator,” said Stephen Hoffman, MD, PhD, Chief Executive Officer of Aerpio. “In June 2017, we initiated our TIME-2b Phase
Riassunto: EyeArt™, il software per lo screening della retinopatia diabetica basato sull’intelligenza artificiale sviluppato da Eyenuk Inc., è stato collaudato con un dispositivo di imaging basato su smartphone portatile in un nuovo studio che ne ha …
LOS ANGELES–(BUSINESS WIRE)–EyeArt™, il software per lo screening della retinopatia diabetica basato sull’intelligenza artificiale sviluppato da Eyenuk Inc., è stato collaudato con un dispositivo di imaging basato su smartphone portatile in un nuovo studio che ne ha dimostrato il potenziale quale strumento di screening di massa della retinopatia altamente sensibile ed economico Eyenuk, Inc., una prestigiosa società impegnata nello sviluppo di soluzioni avanzate basate sull’intelligenza artifi
Global Retinopathy Partnering Directory 2012 to 2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Retinopathy Partnering 2012 to 2018” report has been added to ResearchAndMarkets.com’s offering. The Global Retinopathy Partnering Terms and Agreements since 2012 report provides understanding and access to partneri…
Global Dry Eye Partnering Directory 2012-2018 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Dry Eye Partnering 2012 to 2018” report has been added to ResearchAndMarkets.com’s offering. The Global Dry Eye Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals…
Samenvatting: Nieuw onderzoek naar screeningsoftware EyeArt™ van Eyenuk Inc. met beeldtechnologie in smartphone wijst op de mogelijkheden voor grootschalige zeer sensitieve, maar voordelige netvliescontrole
LOS ANGELES–(BUSINESS WIRE)–Eyenuk, Inc., een toonaangevende ontwikkelaar van geavanceerde klinische oplossingen die ziektes signaleren met behulp van kunstmatige intelligentie en netvliesanalyse, kondigt de publicatie aan van een onderzoek waarbij zijn screeningsoftware EyeArt™ is gebruikt voor netvliesfoto’s van de Remidio Fundus on Phone (FOP), een volgens FDA 510k geregistreerde camera voor fundusfoto’s die smartphones combineert met gepatenteerde optica. Het onderzoek toonde aan dat de t
Improving Malaria Diagnosis Using Artificial Intelligence; VisionQuest Biomedical and Volk Optical Partner to Save Thousands of African Kids’ Lives
ALBUQUERQUE, N.M.–(BUSINESS WIRE)–#ai–VisionQuest Biomedical LLC (Albuquerque, NM) has partnered with Volk Optical (Mentor, OH) to develop a technological solution that could potentially save the lives of hundreds of thousands of children under 5 years old in Africa. Cerebral malaria (CM) is a fatal neurological complication of malaria, claiming hundreds of thousands of children’s lives in Africa every year. Malarial retinopathy is a retinal manifestation of cerebral malaria and its presence in t
Eyenuk Inc.’s AI-Based Diabetic Retinopathy Screening Software EyeArt™ Tested with Portable Smartphone-Based Imaging Device in New Study Indicating Potential for Highly Sensitive Yet Cost-Effective Mass Retinal Screening
LOS ANGELES–(BUSINESS WIRE)–#Remidio–Eyenuk, Inc., a leading developer of advanced clinically supported artificial intelligence (AI) enabled solutions to identify diseases via retinal image analysis, today announced the publication of a study using Eyenuk’s EyeArt™ screening software on retinal images acquired with the Remidio Fundus on Phone (FOP) system, an FDA 510k registered fundus camera which combines a smartphone with patented optics. The study demonstrated very high sensitivity for detecting b